VIA
RAPP

Virtus Investment Advisers’s Rapport Therapeutics RAPP Stock Holding History

Virtus Investment Advisers’s Portfolio RAPP Stock Details RAPP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$355K Sell
8,521
-486
-5% -$17.9K 0.08% 342
2026
Q1 		$282K Buy
9,007
+218
+2% +$6.13K 0.08% 292
2025
Q4 		$267K Sell
8,789
-1,425
-14% -$39.4K 0.07% 300
2025
Q3 		$303K Buy
10,214
+1,773
+21% +$31.6K 0.09% 239
2025
Q2 		$96K Sell
8,441
-196
-2% -$2.08K 0.03% 349
2025
Q1 		$86.6K Buy
+8,637
New +$112K 0.02% 441

Other funds holding RAPP

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
TGV
TRV GP V Boston, Massachusetts $498M AUM 267.53% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

Virtus Investment Advisers's RAPP Position: Q2 2026 in Review

Virtus Investment Advisers reduced its Rapport Therapeutics (RAPP) stake by 5.4% in Q2 2026, selling an estimated $17.9K and leaving 8,521 shares worth $355K. The position accounts for 0.08% of the portfolio, ranked #342.

Virtus Investment Advisers first reported a position in RAPP in Q1 2025 and has held it in 6 quarters since. 160 funds tracked by Wall St. Rank hold RAPP as of Q2 2026.

  • Virtus Investment Advisers held 8,521 shares of Rapport Therapeutics worth $355K as of Q2 2026.
  • Virtus Investment Advisers sold 486 Rapport Therapeutics shares in Q2 2026, an estimated $17.9K.
  • Rapport Therapeutics made up 0.08% of Virtus Investment Advisers's portfolio in Q2 2026, its #342 holding.
  • Virtus Investment Advisers first reported a position in Rapport Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • 160 funds tracked by Wall St. Rank held Rapport Therapeutics as of Q2 2026.

Based on Virtus Investment Advisers's 13F filing for Q2 2026, filed 11 Aug 2026.